公开(公告)号：US20230321103A1

公开(公告)日：2023-10-12

申请号：US18043419

申请日：2021-09-01

Applicant: East China University of Science and Technology

Inventor： Honglin LI ,  Zhenjiang ZHAO ,  Yanyan DIAO ,  Zhuo CHEN

IPC: A61K31/519

CPC classification number: A61K31/519

Abstract: Provided is the use of a series of pteridinones and/or a pharmaceutically acceptable salt and a prodrug thereof as a non-canonical EGFR mutant inhibitor. Specifically, the present invention relates to the use of a series of compounds as represented by formula I and a pharmaceutical composition containing the series of compounds as represented by formula I in the preparation of a drug for treating a disease containing EGFR 20insX mutation, EGFR G719X mutation and ERBB2 mutation.

公开(公告)号：US20200163983A1

公开(公告)日：2020-05-28

申请号：US16630309

申请日：2018-07-12

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY ,  YUNNAN UNIVERSITY ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Honglin LI ,  Weilie XIAO ,  Lili ZHU ,  Lina QUAN ,  Qiao LI ,  Yanyan DIAO ,  Zhenjiang ZHAO ,  Hualiang JIANG

IPC: A61K31/704 ,  A61P35/00 ,  A61K31/56

Abstract: Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease.